The global epigenetics market size is expected to reach $6,460.5 million by 2030, growing at a CAGR of 17.1% from 2021 to 2030. The market is being driven by the strategic initiatives of companies and governments in this field. Several market participants in Europe and the APAC region have received government approvals for epigenomics research. For example, Zymo Research Corporation received the CE IVD Mark approval in September 2021 for its EZ DNA Methylation-Lightning Kit, for use in clinical diagnostics with epigenetic mechanisms.
The PCR category held more than 30% share in the market in 2021. This technique is extensively used to amplify DNA sequences. Due to its ability to identify genetic alterations and mutations in small samples, PCR has been widely used in cancer diagnosis. Furthermore, significant progress has been made in the PCR technology, which has given rise to related technologies, such as real-time PCR (RT-PCR).
RT-PCR is one of the most-reliable and sensitive methods for analyzing cancer biomarkers, allowing end users to generate high-quality insights when performing epigenetic testing. Moreover, because cancer patients are immunocompromised as a result of immunosuppressive therapies, they are at a high risk of infectious diseases, which could lead to further complications. As a result, the demand for RT-PCR tests for infectious disease diagnosis in cancer patients is skyrocketing.
RT-PCR is used to assess immune compatibility, which has a direct impact on epigenetic success. The increasing incidence of immune-associated infections, as well as the technological advancements in RT-PCR, are driving the category’s growth.
Furthermore, an increase in the demand for sequencing and its platforms among research professionals seeking clinically insightful and comprehensive datasets contributed to this category ranking first in terms of revenue in 2021. Additionally, among all the sequencing technologies, NGS dominates the epigenetics market with a more than 75% share.
End users can now manage cancer-related biomarkers with high sensitivity with the NGS technology. Furthermore, the technology provides a shorter turnaround time and high throughput, thus making it possible to effectively manage patients in clinical settings.
The growth of the category is also due to the DNA-methylation sequencing ability of NGS, which is used for disease diagnosis, translational research, and other applications. NGS has been widely used to sequence circulating biomarkers, such as circulating tumor DNA, cell-free DNA (cfDNA), and cell-free RNA (cfRNA), which are found in both cancerous and non-cancerous samples. Because these circulating biomarkers are released by tumors, incorporating NGS can provide a detailed molecular profile of specific diseases.
Market participants have been involved in the launch of new and improved solutions to boost sales, as well as collaborations to expand geographically, in recent years. For instance,
In April 2022, Pacific Biosciences introduced DNA methylation capabilities in the U.S. through its Sequel product line. The addition of this feature to the Sequel system is expected to increase the accessibility of epigenomes via the company's HiFi sequencing.
Major players in the epigenetics market are Thermo Fisher Scientific Inc., Merck KGaA, Illumina Inc., Pacific Biosciences of California Inc., Abcam plc, Active Motif Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., New England Biolabs Inc., F. Hoffmann-La Roche Ltd., and PerkinElmer Inc.